Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01, R21 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.

This FOA will utilize the Research Project Grant (R01) mechanism and runs in parallel with a companion FOA of identical scope, PAR-22-140, which utilizes the Research Exploratory/Developmental Research Grant (R21) mechanism.


  • R01 Due Dates: Feb. 5, Jun. 5, Oct. 5
  • R21 Due Dates: Feb. 16, Jun. 16, Oct. 16

PAR-22-139 Expiration Date May 08, 2025

Agency Website



Amount Description

Application budgets are limited to not exceed $500,000 per year in direct costs and need to reflect the actual needs of the proposed project.

The maximum project period is 5 years.

Funding Type





Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science

External Deadline

February 5, 2024